Gilteritinib Approved in Europe for Relapsed/Refractory FLT3+ AML

October 25, 2019 – The European Commission has approved gilteritinib as a single agent for the treatment of relapsed/refractory patients with FLT3-mutant acute myeloid leukemia (AML). The approval is based on findings from the phase III ADMIRAL trial, which showed that the median overall survival (OS) in patients who were treated with gilteritinib was 9.3 months (95% CI, 7.7-10.7) compared with 5.6 months in those who received salvage chemotherapy … (leggi tutto)